Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
NCI-CCC Tumor Board Question
•
University of Michigan
•
NCI-CCC Lymphoma Tumor Board Question
How would you approach therapy for BR-refractory Waldenstrom Macroglobulinemia when there is a mixed response to zanabrutinib?
Answer from: at Community Practice
It goes without saying this is a “data-free zone.” I would consider extrapolating from CLL and adding venetoclax.
Sign in or Register to read more
13794
Related Questions
In light of data from TRIANGLE, ECHO, and ENRICH, what is the best strategy to treat newly diagnosed patients with the blastoid variant MCL?
How would you manage a patient with marginal zone lymphoma who progress after treatment on a BKTI?
Is there a role for thiotepa-based auto transplant for consolidation in PCNSL if the patient had progression on both MTX and Ara-C?
How would you manage a frail patient with GCB DLBCL who is unable to complete R-CHOP but has moderate residual disease?
What is the best treatment approach to a patient with HGBCL with FISH translocation of BCL-6 and c-Myc given new classification of this entity?
What is the role of surveillance imaging after first line therapy in patients with aggressive lymphomas?
What is your approach to managing follicular lymphoma with central nervous system involvement?
How do you approach patient with CLL/SLL limited to the prostate?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?